The invention relates to eucaryote cells, eucaryote protoplasts and eucaryote pluricellular living organisms having a certain ADN concentration, introduced by means of lipidic vesicles.

The present invention relates to targeted genome editing in eukaryotic cells or organisms.

The present invention provides methods of modulating the expression of eukaryotic genes in eukaryotic cells.

The resulting modified IOBCVs can then be inserted into eukaryotic cells to express the eukaryotic genes.

Also disclosed are nucleic acids encoding such chimeric polypeptides and eukaryotic organisms expressing such chimeric polypeptides.

A process is disclosed for producing mutant proteins of eukaryotic polypeptides in eukaryotic cells by homologous recombination.

Also disclosed is a method and compositions for killing eukaryotic pathogens or converting drug-resistant eukaryotic cells to drug-sensitive cells.

Organisms with eukaryotic cells are known as Eukaryotes.

Organisms with eukaryotic cells are called eukaryotes.

The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells.

The invention relates to the use of prokaryotic beta recombinase in eukaryotic cells, especially for transgenic work in eukaryotic cells.

Organisms with eukaryotic cells are known as Eukaryotes.

The method can be used in eukaryotic cells in vitro or in vivo, for example by constructing transgenic eukaryotic organisms.

A method and a combination for the cultivation of eukaryotic cells are provided, as well as a method for preparation of eukaryotic cells.

The organisms used can be prokaryotic or eukaryotic.